Lucinda Crabtree, Ph.D., joined MorphoSys as Chief Financial Officer in August 2023. She has broad biotech experience from various corporate roles and her time as an investment professional and board observer.

Prior to joining MorphoSys, Lucinda served as the Chief Financial Officer at Autolus Therapeutics, a clinical-stage biopharmaceutical company developing T cell therapies. In her previous roles at Autolus, she led Finance, Business Strategy and Planning, as well as Investor Relations and Corporate Communications functions. Prior to her time at Autolus, Lucinda worked for several years as a senior investment professional on both the buy and the sell sides, and she served as a board observer for several private healthcare companies. Firms she has worked at include Woodford Investment Management, Panmure Gordon, Goldman Sachs, J.P. Morgan and Jefferies.

Lucinda started her career as a research scientist at a U.K.-based biotech company. She holds a first class Bachelor of Science degree in Physiology and Pharmacology from University College London and a Ph.D. in Pharmacology from University College London.